NCT03767452

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

A Phase 4, Single-Center, Multiple-Dose, Open-Label Trial to Evaluate the Efficacy of Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response After Prior Xiaflex® Treatment

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Manhattan Medical Research Practice, PLLC · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.

Conditions

• Peyronie's Disease

Interventions

Type	Name	Description
DRUG	Xiaflex® 0.58 mg	0.25 mL injections.

Timeline

• Start date: 2018-10-04
• Primary completion: 2019-12-01
• Completion: 2020-02-01
• First posted: 2018-12-06
• Last updated: 2018-12-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study